PharmEasy IPO: Why API Holdings withdrew IPO paper, what it said about rights issue? Details here

The initial public offer (IPO) of PharmEasy has been withdrawn after the company received capital market regulator SEBI's (Securities Exchange Board of India) go-ahead in February this year. The IPO was withdrawn due to market conditions and strategic considerations, as per the the company. Now, it plans to raise funds via rights issue. 

API Holdings, the parent entity of PharmEasy, on August 20 announced the withdrawal of the draft red herring prospectus (DRHP). The pre-IPO draft papers were filed on November 9 last year. .  

"The company is committed to its expansion plans, and is considering to raise funds via a rights issue. Shareholders of the company will receive the letter of offer inviting them to participate in the rights issue. The rights issue will be open for a period of 30 days, starting from on or around the first week of September," the company said. 

TRENDING NOW

Top-5 mutual funds that have given the highest returns year to date

Strong tremors in Delhi-NCR after 6.2 magnitude earthquake in Nepal

India's smart TV Shipments fall 5% in H1, estimated to decline 7% in 2023: Report

World Bank estimates Indian economy to grow at 6.3% in FY24; predicts service sector activity to grow at 7.4%

India's smart TV Shipments fall 5% in H1, estimated to decline 7% in 2023: Report

Centre may come up with action plan next week to tame red-hot inflation

AMFI rejig: IRFC, Polycab and Jio Financial Services among others may enter large-cap category, says Nuvama

IND vs NED Free Live Streaming: When and How to Watch India vs Netherlands ODI World Cup 2023 warm-up Match Live on Web, TV, mobile apps online

India is now 2nd-biggest manufacturing hub for mobile phones globally

Senior Citizen Savings Scheme (SCSS): Know how much return you will get on investment from Rs 1 to Rs 15 lakh in SCSS

Hyundai Verna secures top safety rating in Global NCAP crash test

JSW Infrastructure makes strong debut at Dalal Street, shares list at 20% premium

Udyog Aadhaar: What is Udyog Aadhaar? Why is it useful for MSMEs?

ONGC, Oil India under pressure after Centre's windfall tax move; MGL, Gujarat Gas rise post-gas price hike

Swiggy disburses over Rs 450 crore in loans to 8K restaurant owners

Earlier, in its DRHP, PharmEasy had stated that it was planning to raise Rs 6,250 crore from the issue.  The proceeds were to be used for settling an outstanding debt of Rs 1,929 crore, fund organic growth initiatives aggregating to Rs 1,259 crore, pursue inorganic growth through acquisitions and other strategic initiatives totalling Rs 1,500 crore. 

The SEBI had approved the initial public offering of PharmEasy, along with Adar Poonawalla-backed Wellness Forever Medicare and metal recycling firm CMR Green Technologies in mid-February. The three companies were issued observation letters by the market regulator on February 16-17, 2022 after they filed preliminary IPO papers with SEBI between September and November last year.